ofa tirzepatide lawsuit A class-action has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly's blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager informed patients #OnThePen has obtained an exclusive

Superoxide generation from endothelial nitric-oxide synthase

B12 absorption depends on a protein produced in your stomach called intrinsic factor

Patients who combine GLP-1 therapy with CGM monitoring make smarter food choices, stay more motivated, and achieve significantly better outcomes

The studies mainly report results at 24, 40, 48 and 68 weeks, although weight loss was already starting in the early weeks with some users experiencing 2-5% of weight loss in the first 4 weeks

[1] [2] [3] [4] [5] [6] [7] A systematic review and metanalysis of cagrisema, published in 2024, found that cagrisema may provide weight loss benefits